Associations between red blood cell and platelet transfusions and retinopathy of prematurity by Hengartner, Tobias et al.








Associations between red blood cell and platelet transfusions and
retinopathy of prematurity
Hengartner, Tobias ; Adams, Mark ; Pfister, Riccardo E ; Snyers, Diane ; McDougall, Jane ; Waldvogel,
Salome ; Held-Egli, Katrin ; Spring, Lea ; Rogdo, Bjarte ; Riedel, Thomas ; Arlettaz Mieth, Romaine ;
Swiss Neonatal Network
Abstract: AIM: The aim of this study is to examine possible associations between the transfusion of RBC
or platelets (PLTs) and the development of retinopathy of prematurity (ROP) in infants. METHODS:
This retrospective, national, case-control study included all live births in Switzerland between 2013 and
2018. We investigated preterm infants at a gestational age of <28 weeks, who developed higher stage
ROP (฀stage 2, n = 178). Each case infant was matched to another of the same sex who did not develop
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Abstract
Aim: The aim of this study is to examine possible associa-
tions between the transfusion of RBC or platelets (PLTs) and 
the development of retinopathy of prematurity (ROP) in in-
fants. Methods: This retrospective, national, case-control 
study included all live births in Switzerland between 2013 
and 2018. We investigated preterm infants at a gestational 
age of <28 weeks, who developed higher stage ROP (≥stage 
2, n = 178). Each case infant was matched to another of the 
same sex who did not develop ROP (n = 178, control group). 
Results: When compared with the control group, we ob-
served higher numbers of RBC transfusions per infant and 
higher percentages of infants receiving PLT transfusions in 
the case group. An adjusted logistic regression analysis re-
vealed that both RBC (odds ratio [OR] 1.081, 95% confidence 
interval [CI] 1.020–1.146) and PLT transfusions (OR = 2.502, 
95% CI 1.566–3.998) numbers were associated with ROP de-
velopment. Conclusions: Multiple RBC and PLT transfusions 
are associated with higher stage ROP development. Pro-
spective studies are required to determine their potential as 
risk factors. © 2020 The Author(s) 
Published by S. Karger AG, Basel
Introduction
As mortality of extremely preterm infants has de-
creased in recent years [1], comorbidities such as retinop-
athy of prematurity (ROP) are of growing concern. ROP 
is the most common and potentially preventable cause of 
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blindness or visual impairment in childhood and is associ-
ated with worse neurological and cognitive long-term de-
velopmental outcomes [2]. In Switzerland, 1.8% of infants 
born below 32 weeks gestation require ROP treatment, 
representing an internationally low incidence [3, 4].
Postnatally, partial oxygen (O2) pressure levels are 
higher when compared to in utero. This hyperoxic state 
leads to delayed vascularization of the immature retina, 
due to vascular endothelial growth factor (VEGF) sup-
pression. Without adequate blood supply, the metaboli-
cally active retina becomes increasingly hypoxic over 
time, resulting in VEGF and other pro-angiogenic factor 
upregulation, and leading to aberrant vascularization [5].
To prevent these serious complications, it is crucial to 
identify factors increasing their risk. Established risk fac-
tors include low gestational age (GA) and low birth 
weight, especially for infants who have a body weight < 
the 10th percentile [5]. Similarly, O2 administration and 
hyperoxia [5] are further risk factors, while the role of 
sepsis [6] is equivocal. Currently, there is debate on 
whether RBC or platelet (PLT) transfusion increases the 
risk of developing ROP.
Studies have shown that high percentages of preterm 
infants receive blood transfusions [7], with some side ef-
fects including allergic or haemolytic reactions, and the 
release of pro-inflammatory and immunomodulatory 
mediators such as cytokines or VEGF [8]. However, a 
possible association between RBC transfusions and an in-
creased ROP risk remains a subject of controversy, as nei-
ther prospective [9–11] nor retrospective [12–14] data 
analyses have provided consistent, unambiguous results. 
Similarly, other studies have suggested links between 
thrombocytopenia, PLT transfusions, and ROP develop-
ment [15–18]. Our aim was to investigate whether asso-
ciations existed between RBC and PLT transfusions and 
ROP in Switzerland.
Patients and Methods
This was a retrospective, national, case-controlled study in all 
9 neonatal intensive care units in Switzerland. We included all 
Swiss preterm infants (n = 178) born between 2013 and 2018 at a 
GA <28 weeks, who developed stage 2 ROP at least, as defined by 
the International Classification of Retinopathy of Prematurity 
[19].
Each infant in the case group was matched to another of the 
same sex, who did not develop ROP (control group, n = 178). Oth-
er matching criteria included treatment at the same perinatal cen-
tre, GA (same week) and birth weight (same quartile).
Infants were excluded if they had severe congenital malforma-
tions, documented parental refusal to consent, incomplete medical 
records or transfusion data, or the infant died before ROP screen-
ing could be performed. No case infants were lost due to incom-
plete data or parental refusal to consent.
Patient Data and Definitions
Patient characteristics and outcomes were extracted from 
SwissNeoNet. RBC and PLT transfusion data were gathered by lo-
cal investigators from infant medical notes. Major brain lesions 
(defined as intraventricular haemorrhage grade 3 or higher, or cys-
tic periventricular leukomalacia, MBL), bronchopulmonary dys-
plasia (BPD), necrotizing enterocolitis, and late-onset neonatal 
sepsis were defined as previously published [20]. Outborn was de-
fined as a birth outside the perinatal centre. Days on additional O2 
were defined as the number of days where FiO2 > 0.21 was pro-
vided for at least 12 h per day.
Perinatal Centre Guidelines
All infants were screened for ROP. Infants with a haemorrhage 
received a PLT transfusion (10–20 mL/kg of body weight) if their 
PLT levels were <50 G/L and those without haemorrhage if their 
PLT levels reached <20 G/L, respectively. RBC transfusions (10–20 
mL/kg of body weight) were administered depending on haema-
tocrit/haemoglobin levels, the need for O2, cardiopulmonary dis-
ease, and clinical symptoms. Preterm infants routinely received 
erythropoietin (EPO) for treatment of anaemia of prematurity at 
3 perinatal centres involving 3 intravenous/subcutaneous admin-
istrations of 250–400 IU EPO per week. They were evenly distrib-
uted among cases (N = 49) and controls (N = 51). Target blood 
oxygenation levels averaged 87–95%.
Statistics
The χ2 test or Fisher’s exact test was used for categorical and the 
Mann-Whitney U test for metric variables. Effect sizes (r) were 
determined by calculating Phi and Cramer’s V for the χ2 test and 
the rank-biserial correlation for the Mann-Whitney U test. An ad-
justed ordinal logistic regression tested for links between blood 
transfusions and ROP development. We adjusted for GA, birth 
weight (Z scores), sepsis, MBL, and days on additional O2. p values 
<0.05 were considered statistically significant. Statistical analyses 
were performed using the IBM SPSS Statistics 25 USA programme.
Results
Baseline characteristics between case and control 
groups were similar (Table 1), apart from a slightly lower 
mean GA and birth weight, a poorer clinical health in case 
infants with MBL (18 vs. 8%, p = 0.008, r = 0.14), a statis-
tical tendency towards a higher number of days on addi-
tional O2 (71 vs. 68 days, p = 0.074, r = 0.1), a higher rate 
of severe BPD (25 vs. 12%, p = 0.006, r = 0.17), and a more 
frequent administration of BPD steroid treatments (28 vs. 
19%, p = 0.046, r = 0.11). The distribution of these char-
acteristics was reflected by older postmenstrual age upon 
hospital discharge from hospital (42 1/7 weeks of preg-
nancy vs. 41 2/7 weeks of pregnancy, p = 0.004, r = 0.16). 
In the case group, 87 infants (49%) developed severe ROP 
(≥stage 3) of which 50 (57%) were treated.
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In comparison with the overall Swiss source popula-
tion (Table 1), mortality was higher in the source popula-
tion (16%) than in the case and control populations (2% 
each). This concerns infants who died prior to being 
screened for ROP. They were, therefore, excluded. Case 
and control populations comprised patients in poorer 
clinical health than the source population. They had low-
er GA and birth weights, higher rates of severe BPD, more 
days on additional O2, and longer hospital stays.
We observed statistically significant differences be-
tween transfused infants in the case and the control 
groups. The latter received a higher number of RBC 
transfusions per infant (4 vs. 3; p < 0.001, r = 0.26) and 
higher volumes of RBCs per transfusion (57.3 vs. 40.3 mL; 
p < 0.001, r = 0.21). They also received transfusion treat-
ments earlier (at 3 days postnatal age vs. 5 days, p < 0.001, 
r = 0.19) (Table 2). A higher number of infants from the 
case group received 1 or more PLT transfusions (39 vs. 
18%, p < 0.001, r = 0.23) (Table 3), but there was no dif-
ference between groups in terms of the numbers of trans-
fusions per infant, transfusion volumes, and the timing of 
transfusions.
Using a univariable approach, we observed an associa-
tion between ROP and the amount (number/volume) of 
RBC transfusions for infants receiving transfusions and 
for ROP and PLT transfusions. We further tested these 
associations using a logistic regression approach, adjust-
ing for major differences in baseline characteristics, that 
Table 1. Case population demographic data and the Swiss population as a whole










Male, n (%) 717 (52) 103 (58) 103 (58)







Birth weight, g 800 (680–950) 703 (588–792) 737 (620–740) 0.009 0.14
SGA, n (%) 166 (12) 35 (20) 27 (15) 0.264 0.06
Deceased infants, n (%) 220 (16) 4 (2) 3 (2) 0.703 0.02
Outborn, n (%) 73 (5) 1 (1) 4 (2) 0.177 0.07
Multiples, n (%) 382 (28) 61 (34) 46 (26) 0.083 0.08
Section, n (%) 1,084 (79) 155 (87) 145 (82) 0.145 0.08
Surfactant, n (%) 1,124 (82) 162 (91) 158 (89) 0.482 0.04
Antenatal steroids, n (%) 1,261 (93) 171 (96) 167 (94) 0.333 0.05
Steroids for BPD, n (%) 188 (14) 50 (28) 34 (19) 0.046 0.11
EPO to prevent anaemia, n (%) na 49 (28) 51 (29) 0.814 0.01









Sepsis, n (%) 321 (24) 56 (32) 47 (26) 0.293 0.06
MBLs, n (%) 189 (14) 32 (18) 15 (8) 0.008 0.14
Necrotizing enterocolitis, n (%) 95 (7) 15 (8) 11 (6) 0.415 0.04
BPD, n (%)
Moderate 217 (16) 55 (31) 59 (33) 0.006 0.17
Severe 119 (9) 44 (25) 21 (12)
Days on additional O2 37 (10–62) 71 (52–88) 68 (48–80) 0.074 0.1
ROP stage, n (%)
Stage 2 91 (51)
Stage 3 85 (48)
Stage 4 1 (1)
Stage 5 1 (1)
ROP therapy, n (%)
Anti-VEGF 15 (8)
Laser/cryotherapy 35 (20)
ROP, retinopathy of prematurity; BPD, bronchopulmonary dysplasia; MBL, major brain lesion; EPO, erythropoietin; VEGF, vascular 
endothelial growth factor; SGA, small for gestational age; O2, oxygen. Values in parenthesis show the interquartile range. p values and 
the effect size related to case and control groups.




is, sepsis, MBL and days on additional O2 (Tables 4–6). 
As matching does not necessarily control for confound-
ing by matching factors, both GA and birth weight were 
included in logistic regression analyses [21].
The development of severe ROP was associated with 
the number of RBC transfusions per infant (odds ratio 
[OR] = 1.081, 95% confidence interval [CI] 1.020–1.146, 
p = 0.008) and the number of infants who received at least 
1 PLT transfusion (OR = 2.502, 95% CI 1.566–3.998, p < 
0.001). RBC transfusion volumes were less strongly asso-
ciated (OR = 1.001, 95% CI 1.000–1.002, p = 0.182) and 
were, therefore, a worse predictor than the number of 
RBC transfusions.
Discussion
In our retrospective, national, 1:1 matched case-con-
trol study, RBC and PLT transfusions were associated 
with the development of severe ROP, both in primary 
Table 2. RBC transfusion analysis between the case and control groups




p value Effect 
size, r
Infants receiving transfusions, n (%) 162 (91) 154 (87) 0.179 0.07
Transfusions per infant, n 4 3 0.001 0.26
Transfusion volume, mL 57.3 (32.4–97.9) 40.3 (23.8–64.9) <0.001 0.21
Timing of 1st transfusion (postnatal age in days) 3 5 <0.001 0.19
The median is shown for transfusion analysis; the value in parentheses reflects the interquartile range.
Table 3. PLT transfusion analysis between the case and control groups




p value Effect 
size, r
Infants receiving transfusion, n (%) 69 (39) 32 (18) <0.001 0.23
Transfusions per infant 2 3 0.776 0.03
Transfusion volume, mL 27.5 (12.5–63.2) 31.1 (12.5–64.6) 0.710 0.04
Timing of 1st transfusion (postnatal age in days) 5 4 0.205 0.13
PLT, platelet. The median is shown for transfusion analysis; the value in parentheses reflects the interquartile range.
Table 4. Ordinal logistic regression of RBC transfusion volumes/
infant receiving a transfusion
Parameter OR CI (95%) p value
RBC transfusion volume 1.001 1.000–1.002 0.182
GA 0.957 0.930–0.985 0.003
Birth weight (Z score) 1.000 1.000–1.000 0.053
Sepsis 1.072 0.685–1.678 0.762
MBLs 2.100 1.183–3.728 0.011
Days on additional O2 1.002 0.996–1.007 0.544
MBL, major brain lesion; GA, gestational age; OR, odds ratio, 
CI, confidence interval; O2, oxygen.
Table 5. Ordinal logistic regression of the number of RBC 
transfusions/infant receiving a transfusion
Parameter OR CI (95%) p value
RBC transfusions 1.081 1.020–1.146 0.008
GA 0.965 0.937–0.994 0.018
Birth weight (Z score) 1.000 1.000–1.000 0.090
Sepsis 0.932 0.587–1.480 0.765
MBLs 1.939 1.084–3.468 0.026
Days on additional O2 0.999 0.993–1.005 0.841
MBL, major brain lesion; GA, gestational age; OR, odds ratio, 
CI, confidence interval; O2, oxygen.
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analysis and adjusted logistic regression. Infants in the 
case group were less healthy than the corresponding 
Swiss source population <28 weeks gestation. This may 
indicate either a selection bias or confounding. A selec-
tion bias would apply if both case and control groups 
were comparably less healthy than the overall Swiss na-
tional cohort, and both groups had an increased need for 
transfusions. The link between RBC/PLT transfusions 
and ROP could, therefore, be more pronounced than our 
study suggests if the case group were compared to the 
overall Swiss cohort. Confounding would apply if sicker 
infants had a higher risk for developing ROP, and at the 
same time, a higher need for transfusions without trans-
fusions being an intermediate step in the causal pathway 
to ROP. However, the degree of illness of cases and con-
trols was similar in comparison with the overall collec-
tive, the association between transfusions and ROP was 
consistent in primary and adjusted analyses, and the lit-
erature discussed below indicates association. This leads 
us to believe that our study warrants further, prospective 
investigation of the association between transfusions and 
ROP.
RBC Transfusions and Anaemia
Case infants received significantly more RBC transfu-
sions and volumes, when compared to control infants. 
On average, they also received earlier transfusions. Vari-
ous models have sought to explain the influence of RBC 
transfusions on ROP development from a pathogenic 
perspective. In preterm infants, RBC transfusions signifi-
cantly increase adult haemoglobin levels in overall hae-
moglobin. Due to the lower O2 affinity of adult haemo-
globin, this can lead to increased O2 transfer to the tissue, 
inducing hyperoxia of tissue [22]. Other studies have 
shown that multiple RBC transfusions also trigger iron 
overload, potentially contributing to ROP pathogenesis, 
due to increased pro-inflammatory cytokines and oxida-
tive stress [23].
Prospective studies, comparing liberal and restrictive 
RBC transfusion guidelines and associated neonatal out-
comes, have shown that liberal transfusion groups receive 
more transfusions, but no statistically significant differ-
ences are observed in ROP incidences between groups 
[9–11]. However, some retrospective studies have ob-
served associations between RBC transfusions and ROP 
[12–14].
Our logistic regression analysis revealed a statistically 
significant association between MBL and ROP; however, 
there is little evidence in the literature to support this 
finding. However, the literature suggests that an increased 
need for additional O2 is a risk factor for ROP develop-
ment, due to the potential effects of hyperoxia. In con-
trast, an increased O2 requirement plays an important 
role in defining RBC transfusion limits in preterm in-
fants. Consequently, these infants tend to have higher 
transfusion limits, which translates to more RBC transfu-
sions overall. We attempted to correct for this three-way 
relationship by including the number of days on addi-
tional O2 in our logistic regression analysis.
PLT Transfusions
More infants in the case group required 1 or more PLT 
transfusions, using primary and adjusted analyses; thus, 
more infants in this group presented with thrombocyto-
penia severe enough to indicate a PLT transfusion. As our 
study was retrospective, it was not possible to ascertain 
whether ROP associates with the PLT transfusion itself or 
with the condition of thrombocytopenia. However, the 
literature provides possible explanations for both.
For instance, PLT transfusion release cytokines, VEGF 
and other immunomodulatory mediators, and favours 
inflammatory and proliferative processes [8]. Other stud-
ies have shown associations between severe thrombocy-
topenia and ROP development [15–18]. Thrombocyto-
penia in itself triggers the release of pro-inflammatory 
mediators [24]. Furthermore, PLTs carry both pro- and 
anti-angiogenic factors in their granules, which can be 
selectively released. Thus, this process could play an im-
portant role in ROP development [25]. As a result, throm-
bocytopenia could contribute to ROP pathogenesis in the 
initial phase, as reduced pro-angiogenic factors could re-
strict the development of new retinal blood vessels. In the 
2nd phase of ROP development, PLT transfusions could 
inhibit VEGF-induced neovascularization because of an-
ti-angiogenic factor release from transfused PLTs. Larger 
Table 6. Ordinal logistic regression for PLT transfusions for all 
infants
Parameter OR CI (95%) p value
Receiving a transfusion (yes/no) 2.502 1.566–3.998 <0.001
GA 0.959 0.932–0.987 0.005
Birth weight (Z score) 1.000 1.000–1.000 0.094
Sepsis 0.934 0.591–1.475 0.769
MBLs 1.899 1.058–3.408 0.032
Days on additional O2 1.000 0.994–1.006 0.933
MBL, major brain lesion; OR, odds ratio, CI, confidence 
interval; O2, oxygen.




prospective studies are required to assess true causal rela-
tionships.
Strengths and Limitations
Our national study included all premature infants with 
at least stage 2 ROP, in a defined geographical area. Pa-
tient characteristics and comorbidities were clearly de-
fined, well-recorded, and comparable between participat-
ing perinatal centres. As limitations, we list the retrospec-
tive nature of the study and the differences between 
clinics in terms of transfusion guidelines and targets for 
O2 saturation limits. As each infant in the case group was 
matched to another from the same, there were no differ-
ences in treatment approaches between groups.
Conclusions
We observed an association between RBC or PLT 
transfusion and ROP development. Prospective studies 
are required to examine possible causal relationships be-
tween these parameters.
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